PMID- 30134232
OWN - NLM
STAT- MEDLINE
DCOM- 20180918
LR  - 20190212
IS  - 1421-9778 (Electronic)
IS  - 1015-8987 (Linking)
VI  - 49
IP  - 1
DP  - 2018
TI  - Prevalence and Prognostic Significance of HPV in Laryngeal Squamous Cell 
      Carcinoma in Northeast China.
PG  - 206-216
LID - 10.1159/000492858 [doi]
AB  - BACKGROUND/AIMS: Human papillomavirus (HPV) is an etiological risk factor for a 
      subset of head and neck squamous cell carcinomas. HPV has been proven to be a 
      powerful prognostic biomarker for oropharyngeal cancer, but its role in the 
      larynx has not been explored in depth. Here, we sought to evaluate the prevalence 
      and genotype distribution of HPV in patients with laryngeal squamous cell 
      carcinoma (LSCC) in northeast China. METHODS: HPV DNA in specimens from 211 
      patients diagnosed with LSCC was analyzed by the polymerase chain reaction and in 
      situ hybridization, and p16 overexpression was evaluated by immunohistochemistry. 
      p16 expression was scored positive if strong and diffuse nuclear and cytoplasmic 
      staining was present in > 75% of tumor cells. RESULTS: In this study, infection 
      with HPV and p16 expression were not absolutely consistent. Among all patients, 
      132 (62.6%) were positive for HPV DNA (HPV+), while 23 (10.9%) were inconsistent 
      for HPV and p16. Multivariate analysis indicated that HPV, but not p16, is an 
      independent prognostic factor for overall survival in LSCC. Overall survival was 
      significantly improved in HPV+ LSCC patients compared with the HPV-negative group 
      (hazard ratio, 0.395; 95% confidence interval, 0.185-0.843; p = 0.016). Among the 
      132 HPV+ patients, 28 (21.2%) were HPV-16 single infection. CONCLUSION: This 
      study indicates that HPV DNA is a more reliable surrogate marker than p16 for the 
      prediction of survival in patients with LSCC.
CI  - (c) 2018 The Author(s). Published by S. Karger AG, Basel.
FAU - Tong, Fangjia
AU  - Tong F
AD  - Department of Microbiology, Harbin Medical University, Harbin, China.
AD  - Wu Lien-Teh Institute, Harbin Medical University, Harbin, China.
FAU - Geng, Jingshu
AU  - Geng J
AD  - Department of Pathology, Harbin Medical University Cancer Hospital, Harbin, 
      China.
FAU - Yan, Bingqing
AU  - Yan B
AD  - Department of Microbiology, Harbin Medical University, Harbin, China.
AD  - Wu Lien-Teh Institute, Harbin Medical University, Harbin, China.
FAU - Lou, Huihuang
AU  - Lou H
AD  - Department of Microbiology, Harbin Medical University, Harbin, China.
AD  - Wu Lien-Teh Institute, Harbin Medical University, Harbin, China.
FAU - Chen, Xiaohang
AU  - Chen X
AD  - Department of Microbiology, Harbin Medical University, Harbin, China.
AD  - Wu Lien-Teh Institute, Harbin Medical University, Harbin, China.
FAU - Duan, Chenwei
AU  - Duan C
AD  - Department of Microbiology, Harbin Medical University, Harbin, China.
AD  - Wu Lien-Teh Institute, Harbin Medical University, Harbin, China.
FAU - He, Jing
AU  - He J
AD  - Department of Pathology, Harbin Medical University Cancer Hospital, Harbin, 
      China.
FAU - Zhang, Siwei
AU  - Zhang S
AD  - Department of Microbiology, Harbin Medical University, Harbin, China.
AD  - Wu Lien-Teh Institute, Harbin Medical University, Harbin, China.
FAU - Xie, Huanhuan
AU  - Xie H
AD  - Department of Microbiology, Harbin Medical University, Harbin, China.
AD  - Wu Lien-Teh Institute, Harbin Medical University, Harbin, China.
FAU - Li, Huining
AU  - Li H
AD  - Department of Pathology, Harbin Medical University & Department of Pathology, the 
      First Affiliated Hospital of Heilongjiang University of Chinese Medicine, Harbin, 
      China.
FAU - Yuan, Dawei
AU  - Yuan D
AD  - Department of Pathology, Harbin Medical University Cancer Hospital, Harbin, 
      China.
FAU - Zhang, Fengmin
AU  - Zhang F
AD  - Department of Microbiology, Harbin Medical University, Harbin, China.
AD  - Wu Lien-Teh Institute, Harbin Medical University, Harbin, China.
FAU - Meng, Hongxue
AU  - Meng H
AD  - Department of Pathology, Harbin Medical University Cancer Hospital, Harbin, 
      China.
FAU - Wei, Lanlan
AU  - Wei L
AD  - Department of Microbiology, Harbin Medical University, Harbin, China.
AD  - Wu Lien-Teh Institute, Harbin Medical University, Harbin, China.
LA  - eng
PT  - Journal Article
DEP - 20180822
PL  - Germany
TA  - Cell Physiol Biochem
JT  - Cellular physiology and biochemistry : international journal of experimental 
      cellular physiology, biochemistry, and pharmacology
JID - 9113221
RN  - 0 (Cyclin-Dependent Kinase Inhibitor p16)
RN  - 0 (DNA, Viral)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Carcinoma, Squamous Cell/*diagnosis/epidemiology/mortality/virology
MH  - China/epidemiology
MH  - Cyclin-Dependent Kinase Inhibitor p16/metabolism
MH  - DNA, Viral/metabolism
MH  - Female
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Laryngeal Neoplasms/*diagnosis/epidemiology/mortality/virology
MH  - Male
MH  - Middle Aged
MH  - Papillomaviridae/*genetics/isolation & purification
MH  - Prevalence
MH  - Prognosis
MH  - Proportional Hazards Models
OTO - NOTNLM
OT  - Human papillomavirus
OT  - Laryngeal squamous cell carcinomas
OT  - Overall survival
OT  - P16
OT  - Prognosis
EDAT- 2018/08/23 06:00
MHDA- 2018/09/19 06:00
CRDT- 2018/08/23 06:00
PHST- 2017/11/28 00:00 [received]
PHST- 2018/08/13 00:00 [accepted]
PHST- 2018/08/23 06:00 [pubmed]
PHST- 2018/09/19 06:00 [medline]
PHST- 2018/08/23 06:00 [entrez]
AID - 000492858 [pii]
AID - 10.1159/000492858 [doi]
PST - ppublish
SO  - Cell Physiol Biochem. 2018;49(1):206-216. doi: 10.1159/000492858. Epub 2018 Aug 
      22.